Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung

Area of Science:

• Nanotechnology
• Pharmaceutics
• Oncology

Background:

• Poor solubility and bioavailability of etoposide limit its therapeutic efficacy.
• Metastatic cancers require improved drug delivery systems for effective treatment.

Purpose of the Study:

• To develop etoposide-loaded solid lipid nanoparticles (SLN) for enhanced efficacy in treating metastasized cancers.
• To improve the pharmacokinetic and biodistribution profile of etoposide.

Main Methods:

• Solid lipid nanoparticles (SLN) were prepared using the hot homogenization technique with various triglycerides.
• Optimization of process and formulation parameters, including homogenization conditions and lipid type.
• Characterization of nanoparticles for particle size, morphology, drug entrapment, in vitro dissolution, and cytotoxicity (MTT assay).
• In vivo pharmacokinetic, biodistribution, and antimetastatic activity studies in a B16F10 melanoma mouse model.

Main Results:

• Trimysristin was identified as a suitable lipid for nanoparticle fabrication.
• Homogeneous, spherical nanoparticles with approximately 50% drug entrapment were successfully prepared.
• Developed nanoparticles exhibited time- and concentration-dependent cytotoxicity, consistent with in vitro dissolution profiles.
• Pharmacokinetic studies showed increased AUC, t1/2, and MRT, with enhanced drug accumulation in highly perfused organs.
• In vivo studies demonstrated improved tumoricidal activity and survival rates in the B16F10 melanoma mouse model.

Conclusions:

• Solid lipid nanoparticles (SLN) effectively improve etoposide's solubility, bioavailability, and therapeutic efficacy.
• The developed SLN system shows promise for targeted delivery to metastasized tumors.
• This nanotechnology-based approach offers a viable strategy for enhancing etoposide's anticancer activity.